Summary:
Summary Statement of Deficiencies D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of 2021 and 2022 hematology proficiency testing (PT) results reported to the CLIA database by the PT provider and email with the laboratory director, the laboratory failed to successfully participate in PT. See D-tag 2130, unsatisfactory performance in three consecutive hemoglobin PT challenges. D2130 HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of 2021 and 2022 hematology proficiency test (PT) performance and email with the laboratory director, the laboratory failed to achieve satisfactory performance for the hemoglobin (HGB) analyte in three consecutive testing events. Findings: 1. The laboratory obtained an unsatisfactory score of 0 percent for the HGB analyte for the second testing event of 2021. 2. The laboratory obtained an unsatisfactory score of 60 percent for the HGB analyte for the third testing event of 2021. 3. The laboratory obtained an unsatisfactory score of 60 percent for the HGB analyte for the first testing event of 2022. 4. Email with the laboratory director on May 24, 2022 at 2:00 PM confirmed, the laboratory failed to obtain satisfactory performance in three consecutive testing events for the analyte HGB. . -- 2 of 2 --